Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
出版年份 2016 全文链接
标题
Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
作者
关键词
-
出版物
mAbs
Volume 8, Issue 4, Pages 659-671
出版商
Informa UK Limited
发表日期
2016-04-05
DOI
10.1080/19420862.2016.1156829
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- mTOR inhibition in T-cell lymphoma: a path(way) forward
- (2015) A. J. Moskowitz et al. BLOOD
- AGS16F Is a Novel Antibody Drug Conjugate Directed against ENPP3 for the Treatment of Renal Cell Carcinoma
- (2015) F. Donate et al. CLINICAL CANCER RESEARCH
- A phase 1 study of ABT-806 in subjects with advanced solid tumors
- (2015) James M. Cleary et al. INVESTIGATIONAL NEW DRUGS
- EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
- (2015) Denise A. Yardley et al. JOURNAL OF CLINICAL ONCOLOGY
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma
- (2015) K. J. Hamblett et al. MOLECULAR CANCER THERAPEUTICS
- Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models
- (2015) F. Lhospice et al. MOLECULAR PHARMACEUTICS
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading
- (2015) Pavel Strop et al. NATURE BIOTECHNOLOGY
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- Abstract CT233: A first-in-human phase I study of the safety and pharmacokinetic (PK) activity of DEDN6526A, an anti-endothelin B receptor (ETBR) antibody-drug conjugate (ADC), in patients with metastatic or unresectable melanoma
- (2015) Jeffrey R. Infante et al. CANCER RESEARCH
- Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination
- (2015) Rebecca J. Williams et al. PLoS One
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Lorvotuzumab mertansine: antibody-drug-conjugate for CD56⁺ multiple myeloma
- (2014) Jesus Berdeja Frontiers in Bioscience-Landmark
- Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma
- (2014) Nizar M. Tannir et al. INVESTIGATIONAL NEW DRUGS
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
- (2014) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
- (2014) Johanna Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: An Integrated Safety Analysis
- (2014) Véronique Diéras et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- (2013) V. Ribrag et al. CLINICAL CANCER RESEARCH
- Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2013) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Site-specific antibody drug conjugates for cancer therapy
- (2013) Siler Panowski et al. mAbs
- Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
- (2013) Kirsten Achilles Poon et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody–drug conjugates
- (2013) Puja Sapra et al. Expert Review of Clinical Pharmacology
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production
- (2012) J. N. Thon et al. BLOOD
- Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake
- (2012) Boris Gorovits et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting
- (2012) N. Bouganim et al. Current Oncology
- Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
- (2012) Christina M. Annunziata et al. INVESTIGATIONAL NEW DRUGS
- Ocular Toxicity of Targeted Therapies
- (2012) Daniel J. Renouf et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys
- (2011) T. M. Cardillo et al. CLINICAL CANCER RESEARCH
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- Mitosis is not a key target of microtubule agents in patient tumors
- (2011) Edina Komlodi-Pasztor et al. Nature Reviews Clinical Oncology
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates
- (2009) S. V. Govindan et al. CLINICAL CANCER RESEARCH
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- Optimal and consistent protein glycosylation in mammalian cell culture
- (2009) P. Hossler et al. GLYCOBIOLOGY
- EphA2 Immunoconjugate as Molecularly Targeted Chemotherapy for Ovarian Carcinoma
- (2009) Jeong-Won Lee et al. JNCI-Journal of the National Cancer Institute
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma
- (2008) Herbert Riechelmann et al. ORAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started